Clinical trial Recruiting at 1 site Interventional Ages 16 to 60

Bone marrow cells plus Bio-Oss graft for repairing severe jawbone defects

Official title: A Clinical Study of Autologous Bone Marrow Mononuclear Cells Combined With Bio-oss® for the Repair of Severe Maxillofacial Bone Defects

Run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · NCT07852806 · Data updated 2026-11-12

This study tests whether using a patient’s own bone marrow–derived mononuclear cells mixed with Bio-Oss graft can repair severe maxillofacial bone defects in adults aged 18-60.

More Alveolar Bone Loss trials

Quick facts

Study typeInterventional
Ages16 Years to 60 Years
SexAll
Enrollment20 (estimated)
SponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Academic / other
Locations1 site (Nanjing, Jiangsu)
StatusRecruiting
StartedNovember 1, 2022
Main results expectedJanuary 1, 2027
Study endsSeptember 1, 2027
Registry record updatedOctober 1, 2026
Trial IDNCT07852806 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-60 with severe alveolar bone resorption requiring bone grafting and no major systemic diseases or contraindications to the procedure.

Probably not a fit

Patients with poor oral hygiene, concurrent systemic illness, or conditions that affect bone healing may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, single-arm, open-label study conducted at Nanjing Drum Tower Hospital to assess the safety and potential benefit of autologous bone marrow–derived mononuclear cells combined with Bio-Oss bone graft for repairing severe alveolar/jaw bone loss. About 20 eligible adults will undergo 60 mL of autologous bone marrow aspiration, isolation of BMMNCs without expansion, and implantation with Bio-Oss covered by a collagen membrane, followed by postoperative imaging and scheduled follow-ups. Outcomes will include imaging-based assessment of new bone formation and monitoring for adverse events over the follow-up period. The approach aims to shorten treatment timelines and reduce biosafety risks by avoiding in vitro cell expansion.

Why it matters

Potential benefit: If successful, patients may experience improved bone regeneration and better restoration of jaw function with a potentially shorter treatment process.

How similar studies have gone: Similar cell-based grafting approaches have shown promise in bone regeneration, though this exact BMMNC plus Bio-Oss strategy is relatively novel for maxillofacial defects.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with severe alveolar bone resorption caused by inflammation, trauma, or other reasons, requiring bone grafting;
* Aged 18 to 60 years;
* No systemic diseases such as hypertension, diabetes, heart disease, or immunodeficiency;
* Fully informed of the entire study process, willing to participate, and able to sign the informed consent form.

Exclusion Criteria:

* Patients without maxillofacial bone defects;
* Patients with systemic diseases such as hypertension, heart disease, or diabetes;
* Patients who have recently received immunosuppressive therapy;
* Women who are planning pregnancy, pregnant, or breastfeeding;
* Patients with allergic constitution or a history of allergy to drugs or food;
* Patients with poor oral hygiene habits who cannot comply with medical advice, which may affect efficacy assessment;
* Patients who have participated in other clinical trials within the past 4 weeks.

Where it's running

  • Nanjing Drum Tower Hospital, Nanjing University Medical School
    Nanjing, Jiangsu, China
    Recruiting

Study contacts

  • Principal investigator: Haiyan Qin, MD — Nanjing Drum Tower Hospital, Nanjing University Medical School
  • Study coordinator: Dongyu Bao
  • Email: baodongyu_anson@163.com
  • Phone: 15651989007

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.